6620 Stock Overview
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Handa Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$133.50 |
52 Week High | NT$206.00 |
52 Week Low | NT$105.00 |
Beta | 1.37 |
1 Month Change | -18.10% |
3 Month Change | -26.45% |
1 Year Change | -18.10% |
3 Year Change | 352.54% |
5 Year Change | 272.91% |
Change since IPO | 42.02% |
Recent News & Updates
Shareholder Returns
6620 | TW Pharmaceuticals | TW Market | |
---|---|---|---|
7D | 0% | -1.5% | -0.6% |
1Y | -18.1% | 8.8% | 29.2% |
Return vs Industry: 6620 underperformed the TW Pharmaceuticals industry which returned 8.8% over the past year.
Return vs Market: 6620 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
6620 volatility | |
---|---|
6620 Average Weekly Movement | 7.4% |
Pharmaceuticals Industry Average Movement | 3.8% |
Market Average Movement | 4.7% |
10% most volatile stocks in TW Market | 8.7% |
10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6620's share price has been volatile over the past 3 months.
Volatility Over Time: 6620's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Toshiyo Chen | www.handapharma.com.tw |
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products.
Handa Pharmaceuticals, Inc. Fundamentals Summary
6620 fundamental statistics | |
---|---|
Market cap | NT$18.84b |
Earnings (TTM) | NT$726.89m |
Revenue (TTM) | NT$1.11b |
25.9x
P/E Ratio17.0x
P/S RatioIs 6620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6620 income statement (TTM) | |
---|---|
Revenue | NT$1.11b |
Cost of Revenue | NT$1.30m |
Gross Profit | NT$1.11b |
Other Expenses | NT$378.13m |
Earnings | NT$726.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 5.15 |
Gross Margin | 99.88% |
Net Profit Margin | 65.70% |
Debt/Equity Ratio | 0% |
How did 6620 perform over the long term?
See historical performance and comparison